Mandatory items		Optional items
Methods
Study design	· Parallel group RCTi.e. people randomised to treatment · Within‐person RCTi.e. eyes randomised to treatment · Cluster RCTi.e. communities randomised to treatment · Cross‐over RCT · Other, specify	Number of study arms Method of randomisation Exclusions after randomisation Losses to follow‐up Number randomised/analysed Method of masking How were missing data handled? e.g. available case analysis, imputation methods Reported power calculation (Y/N), if yes, sample size and power Unusual study design/issues
Eyes Unit of randomisation/ unit of analysis	· One eye included in study, specify how eye selected · Two eyes included in study, both eyes received same treatment, briefly specify how analysed (best/worst/average/both and adjusted for within person correlation/both and not adjusted for within person correlation) and specify if mixture of one eye and two eyes · Two eyes included in study, eyes received different treatments,specify if correct pair‐matched analysis done
Participants
Country	‐	Setting Ethnic group Method of recruitment Participation rate Equivalence of baseline characteristics (Y/N) Diagnostic criteria
Total number of participants	This information should be collected for total study population recruited into the study. If these data are reported for the people who were followed up only, please indicate.
Number (%) of men and women
Average age and age range
Inclusion criteria	‐
Exclusion criteria	‐
Interventions
Intervention (n = ) Comparator (n = )	· Number of people randomised to this group · Intervention name · Comparator name · Specify whether phacoemulsification, or other intervention, performed at same time as intervention	Comparator parameters, e.g. dosage of drugs
Outcomes
Primary and secondary outcomes as defined in study reports	· IOP at baseline · IOP at follow‐up · Number of glaucoma medications at baseline · Number of glaucoma medications at follow‐up · Intraoperative complications · Postoperative complications or secondary surgery · Duration of follow‐up · Loss to follow‐up · Intervals at which outcomes assessed Adverse events reported (Y/N)	Planned/actual length of follow‐up
Notes
Date conducted	Specify dates of recruitment of participants mm/yr to mm/yr	Full study name: (if applicable) Date of publication Reported subgroup analyses (Y/N) Were trial investigators contacted?
Sources of funding	‐
Declaration of interest	‐